Drug Profile


Alternative Names: ACA 125; Anti-idiotype ovarian cancer vaccine; MAb ACA 125; Monoclonal Anti-idiotype Antibody ACA125

Latest Information Update: 22 Jul 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator CellControl Biomedical Laboratories
  • Developer Menarini
  • Class Cancer vaccines; Monoclonal antibodies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Ovarian cancer; Pancreatic cancer

Most Recent Events

  • 22 Jul 2015 Discontinued - Phase-III for Ovarian cancer in USA and European Union (SC)
  • 23 Jul 2013 Phase-III development appears to be ongoing for Ovarian cancer in US and European Union
  • 17 Nov 2011 Menarini terminates the phase III MIMOSA trial in Ovarian cancer in USA and European Union (NCT00418574)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top